Virtual Press Conference: FDA Clears AGT to Begin Phase 1 Clinical Trial of HIV Cure Program

AGT was excited to announce its clearance by the FDA to begin a Phase I Trial for an HIV cure. The company hosted a virtual press conference to answer questions from reporters. Here is a video recording of the press conference. In this video we will walk through the:

1. AGT103-T autologous cell therapy
2. Pre-clinical results and peer reviewed publications
3. Clinical sites, enrollment plan, and timelines